🇺🇸 FDA
Patent

US 9765337

Phosphoribosyl pyrophosphate synthetase 2 (PRPS2) as a therapeutic target in cancer treatment

granted A61PA61P35/00

Quick answer

US patent 9765337 (Phosphoribosyl pyrophosphate synthetase 2 (PRPS2) as a therapeutic target in cancer treatment) held by The Regents of the University of California expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Sep 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61P, A61P35/00